Medical devices, healthcare technology and the business of care
510(k) clearance · K260429

Control-IQ+ technology

Tandem Diabetes Care, Inc. · Decision date Apr 24, 2026

FDA DECISIONK260429

What did the FDA decide?

FDA records K260429 as a 510(k) premarket notification, with a decision dated Apr 24, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Clinical Chemistry
Decision date
Apr 24, 2026

FDA source record

Regulatory record facts

Identifier
K260429
Regulatory pathway
510(k) premarket notification
Product code
QJI
Decision code
SESE
Decision date
Apr 24, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Interoperable Automated Glycemic Controller.

Product code
QJI
FDA device class
2

FDA decision timeline

  1. K260429 received

    Application receipt date recorded by FDA.

  2. K260429 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code QJI

Product / regulatory recordCompanyPathwayDecision dateSource
Deka Research and Development Corp.510(k) clearanceOct 15, 2026FDA
CamDiab510(k) clearanceSep 16, 2026FDA
Beta Bionics, Inc.510(k) clearanceSep 11, 2026FDA
Medtronic Minimed510(k) clearanceJul 9, 2026FDA
Insulet Corporation510(k) clearanceJun 29, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Tandem Diabetes Care, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
San Diego, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records